title: Serum IgG, IgM, and IgA reactivity to human papillomavirus types 11 and 6 virus-like particles in different gynecologic patient groups.
abstract: Serum samples from several groups of patients attending a gynecology clinic were analyzed by ELISA for specific antibodies recognizing surface epitopes on intact human papillomavirus (HPV) types 6 and 11 L1 virus-like particles (VLPs) that were synthesized in vitro. In these samples, positive IgG and IgM reactivities to HPV-11 L1 VLPs were, respectively, 12% and 6% for 87 controls, 46% and 67% for 79 condyloma patients, 30% and 64% for 72 cervical intraepithelial neoplasia patients, 16% and 19% for 63 pregnant women at time of delivery, and 5% and 0 in their 63 newborns. IgA reactivities were low and not significantly different. The prevalence of IgG-positivity in HPV-6/11 DNA-positive patients increased from 46% with HPV-11 L1 VLPs to 76% when the sera were additionally screened with HPV-6 L1 VLPs. These data show that HPV-6 and -11 L1 VLPs are effective antigens for serologic studies and they detect type-specific antibodies.
authors.affiliation: Department of Obstetrics and Gynecology, University Clinic Innsbruck, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Heim
authors.forename: N D
authors.initials: ND
authors.lastname: Christensen
authors.forename: R
authors.initials: R
authors.lastname: Hoepfl
authors.forename: B
authors.initials: B
authors.lastname: Wartusch
authors.forename: G
authors.initials: G
authors.lastname: Pinzger
authors.forename: A
authors.initials: A
authors.lastname: Zeimet
authors.forename: P
authors.initials: P
authors.lastname: Baumgartner
authors.forename: J W
authors.initials: JW
authors.lastname: Kreider
authors.forename: O
authors.initials: O
authors.lastname: Dapunt
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D002213:Capsid / Q000276:immunology*; D036022:Capsid Proteins; D016022:Case-Control Studies; D003218:Condylomata Acuminata / Q000276:immunology / Q000821:virology; D000939:Epitopes; D005260:Female; D005831:Genital Diseases, Female / Q000276:immunology / Q000821:virology*; D006801:Humans; D007070:Immunoglobulin A / Q000096:biosynthesis; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D007231:Infant, Newborn; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology; D030361:Papillomavirus Infections / Q000276:immunology / Q000821:virology*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000276:immunology / Q000821:virology; D014764:Viral Proteins; D014771:Virion / Q000276:immunology*; D002578:Uterine Cervical Dysplasia / Q000276:immunology / Q000821:virology
chemical_list: D000914:Antibodies, Viral; D036022:Capsid Proteins; D000939:Epitopes; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; C085217:L1 protein, Bovine papillomavirus; C094776:L1 protein, Human papillomavirus type 11; D009856:Oncogene Proteins, Viral; D014764:Viral Proteins; C091560:L1 protein, Human papillomavirus type 6